Advertisement!
Author Information Pack
Editorial Board
Submit article
Special Issue
Editor's selection process
Join as Reviewer/Editor
List of Reviewer
Indexing Information
Most popular articles
Purchase Single Articles
Archive
Free Online Access
Current Issue
Recommend this journal to your library
Advertiser
Accepted Articles
Search Articles
Email Alerts
FAQ
Contact Us
Pediatrics Education and Research

Volume  3, Issue 4, October - December 2015, Pages -
 

Original Article

BCG Vaccine

Ninza Rawal*, Sunil Mhaske**, Pratap Patare***, Liza Bulsara*

*Post- Graduate **Professor & Head **Associate Professor., Department of Paediatrics, PDVVPF’s Medical College, Ahmednagar.

Choose an option to locate / access this Article:
90 days Access
Check if you have access through your login credentials.        PDF      |
|

Open Access: View PDF

DOI: DOI: https://dx.doi.org/10.21088/per.2321.1644.3415.4

Abstract

 Tuberculosis (TB) is still responsible for 2 million deaths every year despite being a treatable airborne infectious disease. “Consumption” and “Phthisis” were terms historically used to describe TB, which was responsible for one in four deaths in the 19th century. Due to its infectious nature, chronic progression and long treatment, TB is a great burden for society. Moreover the emergence of multi-drug resistant TB and the current TB-HIV epidemic has raised even greater concern. Treating and preventing TB has become a permanent challange since the ancient times. Bacille Calmette-Guérin (BCG) is the only vaccine available today and has been used for more than 90 years with astonishing safety records. However, its efficacy remains controversial. No universal BCG vaccination policy exists, with some countries merely recommending its use and others that have implemented immunization programs. 


Corresponding Author : Ninza Rawal*